Arizona State Retirement System Provention Bio, Inc. Transaction History

Arizona State Retirement System

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	BUY	$6.7 - $24.21 $14,338 - $51,809	2,140 Added 9.79%	24,000 $578,000
Q4 2022 Feb 07, 2023	BUY	$4.52 - $10.57 $31,947 - $74,708	7,068 Added 47.78%	21,860 $231,000
Q3 2022 Nov 07, 2022	BUY	$3.43 - $5.62 $665 - $1,090	194 Added 1.33%	14,792 $67,000
Q2 2022 Jul 28, 2022	BUY	$3.65 - $7.3 $6,387 - $12,775	1,750 Added 13.62%	14,598 $58,000
Q1 2022 May 04, 2022	BUY	$3.4 - $7.88 $187 - $433	55 Added 0.43%	12,848 $94,000
Q4 2021 Feb 04, 2022	SELL	$5.59 - $7.39 $860 - $1,138	-154 Reduced 1.19%	12,793 $72,000
Q3 2021 Nov 12, 2021	SELL	$5.66 - $8.33 $2,371 - $3,490	-419 Reduced 3.13%	12,947 $83,000
Q2 2021 Aug 02, 2021	SELL	$6.71 - $11.04 $2,221 - $3,654	-331 Reduced 2.42%	13,366 $113,000
Q1 2021 May 06, 2021	BUY	$10.12 - $19.45 $22,992 - $44,190	2,272 Added 19.89%	13,697 $144,000
Q4 2020 Jan 28, 2021	SELL	$11.79 - $18.94 $2,428 - $3,901	-206 Reduced 1.77%	11,425 $194,000
Q3 2020 Nov 05, 2020	BUY	$10.34 - $15.2 $120,264 - $176,791	11,631 New	11,631 $149,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

Stay updated on Arizona State Retirement System with notifications on news.